Heron Therapeutics is a commercial-stage biotechnology company that develops and commercializes therapeutic products for acute care and oncology patients. The company's portfolio includes ZYNRELEF, a dual-acting local anesthetic for postoperative pain management; APONVIE, an intravenous formulation of aprepitant for postoperative nausea and vomiting; CINVANTI, an intravenous NK1 receptor antagonist for chemotherapy-induced nausea and vomiting; and SUSTOL, an extended-release 5-HT3 receptor antagonist for chemotherapy-induced nausea and vomiting. Heron utilizes its proprietary Biochronomer Technology to deliver sustained-release pharmacological agents. The company serves the U.S. market, distributing its products through specialty distributors and wholesalers to healthcare providers and hospitals. In January 2024, Heron entered into a co-promotion agreement with Crosslink Network to expand the sales network for ZYNRELEF in orthopedic indications.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Biotechnology Homepage herontx.com
Sector Healthcare IR page ir.herontx.com
Tags
postoperative pain management, chemotherapy-induced nausea and vomiting, postoperative nausea and vomiting, local anesthetics, nk1 receptor antagonists, 5-ht3 receptor antagonists, extended-release formulations, intravenous formulations, oncology care, acute care, ZYNRELEF, APONVIE, CINVANTI, SUSTOL, Biochronomer Technology, Crosslink Network
Press page —

Metrics

Valuation  
Market cap $ 59.651M
Market cap (USD) $ 59.651M
P/E -2.85
PEG —
P/BV 12.13
P/S 0.40
P/OCF -4.34
P/FCF -4.15
Dividend yield —
Turnover / mcap —
Returns  
ROE -140.9%
ROI -13.0%
ROIC -1.2%
Profit margin -13.0%
Growth  
Revenue growing Yes
Profits growing No
Revenue up 3y Yes
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding Yes
Buying back stock No
Diluting (TTM) Yes
Debt/Equity 981.2%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 4
Quality score -47.1%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000
Revenue 154.904M 144.285M 127.044M 107.672M 86.346M 88.6M 146M 77.474M 30.767M 1.279M — — — — — — 1.261M — — — 5.391M 5.404M 4.848M 5.815M 4.387M 3.366M
Net profit -20.195M -13.58M -110.559M -182.024M -220.683M -227.278M -204.749M -178.84M -197.484M -173.143M -97.591M -76.367M -55.283M -23.348M -11.814M -7.346M -10.028M -23.125M -20.163M 5.266M -8.21M -9.221M -4.363M -3.778M -2.514M 8.552M
Free cash flow -27.908M -24.235M -60.334M -148.737M -206.376M -191.633M -131.734M -200.976M -172.853M -137.232M -79.612M -61.72M -42.448M -17.981M -8.234M -5.561M -11.001M -24.573M -17.762M 8.994M -7.843M -7.936M -6.776M -5.561M -6.768M -3.295M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000
Share price 1.3 1.53 1.7 2.5 9.13 21.17 23.5 25.94 18.1 13.1 26.7 10.06 — — — — — — — — — — — — — —
Price performance 12m -0.15 -0.1 -0.32 -0.73 -0.57 -0.1 -0.09 0.43 0.38 -0.51 1.65 — — — — — — — — — — — — — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) 1.96M 41.9M 64.7M 39.9M 41.9M 35.5M 52M 60.1M 78.9M 89.6M
↳ YoY growth +2,036.4% +54.4% -38.3% +4.9% -15.2% +46.6% +15.5% +31.2% +13.6%
↳ 5y CAGR +78.5% +4.4% -1.4% +14.6% +16.4%
Lease liabilities (USD) — — 14.5M 14.2M 17.6M 10.4M 8.19M 5.88M 3.04M 0.00
Cash and deposits (USD) 13.4M 145M 31.8M 71.9M 105M 90.5M 15.4M 28.7M 25.8M 28.6M
Right-of-use assets (USD) — — 13.7M 13.8M 16.3M 9.83M 7.65M 5.44M 2.79M 0.00
Cash flow detail
Operating cash flow (USD) -134M -170M -192M -125M -185M -203M -147M -58.8M -22.5M -27.6M
Purchases of property, plant and equipment (USD) -3.14M -2.55M -9.17M -7.15M -6.81M -3.02M -1.83M -1.55M -1.71M -317,000
Change in receivables (cash effect) (USD) -1.96M -39.9M -22.8M 24.8M -1.97M 6.35M -16.6M -8.09M -18.7M -10.7M
Change in inventories (cash effect) (USD) -5.34M -4.77M -29.1M 14.1M -16.9M -6.48M -6.19M 12.5M -11.1M -31.1M
Change in payables (cash effect) (USD) 3.51M 12M -1.91M -14.1M -2.23M 3.28M -578,000 15,000 8.47M -2.72M
Interest paid (cash effect) (USD) -1.62M -2.79M -1.18M — — -1.24M -2.25M -3.06M -4.86M -6.51M
Share-based compensation (USD) 26M 30.5M 33.4M 51.4M 50.2M 46.9M 43M 32.9M 13M 10.3M
Operating cash flow before change in receivables (USD) -132M -130M -169M -149M -183M -210M -130M -50.7M -3.79M -16.9M
Free cash flow (OCF - PPE - intangibles) (USD) -137M -173M -201M -132M -192M -206M -149M -60.3M -24.2M -27.9M
Income detail
Research and development expense (USD) 103M 139M 140M 167M 175M 131M 108M 55.9M 16.7M 12.4M
↳ 5y CAGR +65.9% +55.9% +33.7% +25.0% +23.3% +4.9% -5.0% -16.8% -36.9% -41.0%
Total comprehensive income (USD) -173M -197M -179M -205M -227M -221M -182M -111M -13.6M -20.2M
Comprehensive income to owners (USD) -173M -197M -179M -205M -227M -221M -182M -111M -13.6M -20.2M
Reported Feb 23, 2017 Feb 27, 2018 Mar 2, 2020 Mar 2, 2020 Feb 24, 2021 Feb 28, 2022 Mar 29, 2023 Mar 12, 2024 Feb 27, 2025 Feb 26, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

•Q3 2026 net revenue of $35.3 million; ZYNRELEF® net revenue up 13.8% and APONVIE® net revenue up 49.3% compared to the third quarter of 2025

•Entered into a definitive agreement under which CorMedix Therapeutics will acquire substantially all of Heron’s assets, announced separately today

CARY, N.C., November 9, 2026 (GLOBE NEWSWIRE) - Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care, today announced financial results for the three and nine months ended September 30, 2026 and recent corporate updates.

Business Highlights

•Heron generated total net revenue of $35.3 million in Q3 2026, compared to $38.2 million in Q3 2025 and $37.7 million in Q2 2026. Heron ended the third quarter with $23.4 million in cash, cash equivalents and short-term investments.

•Acute Care franchise updates: Net revenue increased 22.5% year-over-year for the three months ended September 30, 2026 and increased 32.4% year-over-year for the nine months ended September 30, 2026.

Adds four commercial-stage products — ZYNRELEF®, APONVIE®, CINVANTI® and SUSTOL® — to CorMedix's hospital- and acute-care-focused commercial platform

Upfront consideration consisting of $145 million in cash, subject to customary purchase price adjustments, plus 14,583,333 shares of CorMedix common stock

Additional consideration of up to $55 million in earn-out payments to Heron tied to calendar year 2028 ZYNRELEF net sales plus a royalty on net sales of certain products above a sales threshold

Transaction expected to be immediately accretive to CorMedix earnings and free cash flow, as well as estimated to generate $45-$60 million in near-term total operating cost synergies

CorMedix entered into a new senior secured term loan facility with funds managed by Pharmakon Advisors and will draw $75 million of non-dilutive financing to support the transaction

Heron to remain a publicly traded company with its credit facility repaid, a significant position in CorMedix common stock and rights to earn-out and royalty payments

Transaction expected to close in the first quarter of 2027, subject to regulatory clearance and approval by Heron stockholders and other customary closing conditio

10/26/2026 |

PDF Version

CARY, N.C., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced that the Company will host a conference call and live webcast on Monday, November 9, 2026, at 8:30 a.m. ET to report third quarter financial results and discuss recent business highlights.

The conference call can be accessed by phone by utilizing the following registration link which will provide participants with dial-in details. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. The conference call will also be available via webcast under the Investor Relations section of Heron’s website at www.herontx.com. An archive of the teleconference and webcast will also be made available on Heron’s website for 60 days following the call.

About Heron Therapeutics, Inc.

Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care. Our advanced science, patented technologies, and innovative approach to drug discovery and development have allowed us to create and commercialize a portfolio of products that aim to advance the standard-of-care for acute care and oncology patients. For more information, visit www.herontx.com.

Forward-looking Statements

This news release contains “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995. Heron cautions readers that forward-looking statements are based on management’s expectations and assumptions as of the date of this news release and are subject to certain risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, but are not limited to, risks and uncertainties identified in the Company’s filings with the Securities and Exchange Commission. Forward-looking statements reflect our analysis only on their stated date, and Heron takes no obligation to update or revise these statements except as may be required by law.

Investor Relations and Media Contact:

Ira Duarte Executive Vice President, Chief Financial Officer Heron Therapeutics, Inc. [email protected] 858-251-4400

Print Page

Sign-Up for Email Updates

Receive news and updates on Heron’s latest innovations.

Prompts

Heron Therapeutics, Inc. (ticker HRTX), listed in United States.

Company History

Date Change Detail
Jan 13, 2014 Renamed AP PHARMA INC /DE/ → HERON THERAPEUTICS, INC. /DE/
May 14, 2001 Renamed ADVANCED POLYMER SYSTEMS INC /DE/ → AP PHARMA INC /DE/